Is the antidepressive effect of second-generation antidepressants a myth? (Q43674378)

25 November 2017

0 references

Is the antidepressive effect of second-generation antidepressants a myth? (English)

1 reference

25 November 2017

P Bech

1

0 references

language of work or name

English

0 references

publication date

1 February 2010

1 reference

25 November 2017

Psychological Medicine

1 reference

25 November 2017

40

1 reference

25 November 2017

181-186

1 reference

25 November 2017

2

1 reference

Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.

25 November 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Depressive Illness in a General Practice. A Demographic Study and a Controlled Trial of Imipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Quantitative rating of depressive states

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Fifty years with the Hamilton scales for anxiety and depression. A tribute to Max Hamilton.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Psychotropic drugs and the ‘anti-depressed’ personality

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

The treatment of depressive states with G 22355 (imipramine hydrochloride).

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Desvenlafaxine extended release

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Development of a Rating Scale for Primary Depressive Illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Efficacy of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Facet theoretic analysis of the Hamilton-D scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Clinical use of the Hamilton Depression Rating Scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

Responsiveness to change: an aspect of validity, not a separate dimension

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

The Hamilton depression scale. Evaluation of objectivity using logistic models

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

Antidepressants on trial: how valid is the evidence?

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

Assessment of symptom change from improvement curves on the Hamilton depression scale in trials with antidepressants

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

Taking the measure of anxiety and depression. Validity of the reconstructed Hamilton scales

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

Prevention of first-episode depression: progress and potential

1 reference

https://api.crossref.org/works/10.1017%2FS0033291709006102

7 January 2021

10.1017/S0033291709006102

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

19490744